TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01717638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
Study: NCT02469909

Intervention type: OTHER
Group type: OTHER
Intervention: outpatient clinic follow ups
Description: all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation

Intervention type: OTHER
Group type: OTHER
Intervention: outpatient clinic follow ups
Description: all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate decannulation
Description: the tracheostomy tube is removed at once

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gradual tracheostomy tube decrease
Description: The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
Study: NCT02451319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Endoscopic treatment of Kidney Stones

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Endoscopic treatment of Kidney Stones

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Endoscopic treatment of Kidney Stones
Study: NCT02311478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T380A Intrauterine Copper Contraceptive
Description: The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
Study: NCT01136915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol 370
Description: one time administration for PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol 320
Description: Iodixanol 320 single injection for percutaneous coronary injection
Study: NCT03148340

Intervention type: DIAGNOSTIC_TEST
Intervention: VIPS Monitoring
Description: Bioimpedance asymmetry
Study: NCT03240380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: joint crisis plan
Description: Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: crisis card
Description: Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office.
Study: NCT00954083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIR/Floortime
Description: Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care
Study: NCT03963882

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Description: Concurrent radiochemotherapy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pathologic evaluation
Description: Pathologic evaluation for RH patients
Study: NCT02120079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotemax
Description: Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
Description: Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: In Vivo Confocal Microscopy (IVCM)
Description: In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: In Vivo Confocal Microscopy (IVCM)
Description: In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
Study: NCT00983970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive video game cycling
Description: Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling to Music
Description: Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
Study: NCT02962466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC-Test
Description: classification of the oocyte based on the expression pattern observed in the cumulus cells
Study: NCT02819388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive counseling
Description: A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
Study: NCT01430884

Intervention type: OTHER
Intervention: Aspirated Coronary Blood
Description: Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
Study: NCT04940221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: Telephone delivered non-persuasive shared decision-making for lung cancer screening.
Study: NCT00392041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 3mg qpm for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill qpm for 12 weeks
Study: NCT02272270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline with chemoradiation (temozolomide and radiation therapy)
Description: Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
Study: NCT03474575

Intervention type: OTHER
Group type: OTHER
Intervention: Prevention
Description: The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
Study: NCT05982119

Intervention type: DEVICE
Group type: OTHER
Intervention: ActiMyo/Syde
Description: The two watches can be worn as wristwatch or placed near the ankle and on the wheelchair.~* Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months.~* Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months.~* Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion.~* Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion.
Study: NCT03575156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample
Description: 6 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample
Description: 6 ml
Study: NCT01670006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Nucleus Cochlear Implant System
Study: NCT01081990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclobenzaprine
Description: Cyclobenzaprine 5 mg TID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclobenzaprine
Description: Cyclobenzaprine 5 mg TID for 7 days
Study: NCT00230737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 0.4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 4.0 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03776786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)
Study: NCT03963882

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pathologic evaluation
Description: Pathologic evaluation for RH patients
Study: NCT03776786

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo
Study: NCT01717638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
Study: NCT04372238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAPIDS Intervention
Description: RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard OEND
Description: In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard OEND
Description: In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
Study: NCT04619407

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: SARS-CoV-2 PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: SARS-CoV-2 PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: SARS-CoV-2 PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: SARS-CoV-2 PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum testing
Description: Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum testing
Description: Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
Study: NCT03707561

Intervention type: DIAGNOSTIC_TEST
Intervention: Right Heart Catheterization (RHC)
Description: RHC at the enrollment and every 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Right Heart Catheterization (RHC)
Description: RHC at the enrollment and every 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Right Heart Catheterization (RHC)
Description: RHC at the enrollment and every 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Right Heart Catheterization (RHC)
Description: RHC at the enrollment and every 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Right Heart Catheterization (RHC)
Description: RHC at the enrollment and every 12 months
Study: NCT04101890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diaper care with Theraworx
Description: Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
Study: NCT04101812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD)
Description: PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1
Description: PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
Study: NCT04191668

Intervention type: DEVICE
Group type: OTHER
Intervention: NightOwl
Description: The NightOwl is a finger-mounted home sleep apnea testing device
Study: NCT03397186

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: OTHER
Intervention: Trabectedin
Description: Given as standard of care
Study: NCT01760434

Intervention type: OTHER
Group type: OTHER
Intervention: Long-term outcomes
Description: Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
Study: NCT01887912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile Toxoid Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 0.9% normal saline
Description: 0.5 mL, Intramuscular
Study: NCT03808155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: The drug ist taken once a day per os five days prior to the operation and two days after the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
Study: NCT06556108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALPP CAR-T cells
Description: T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT04199923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single leg immobilisation
Description: Immobilisation with single leg suspension immobilisation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single leg immobilisation
Description: Immobilisation with single leg suspension immobilisation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single leg immobilisation
Description: Immobilisation with single leg suspension immobilisation
Study: NCT03815292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMH-MAP
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT02241486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Fentanyl Spray
Description: Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
Study: NCT01934504

Intervention type: PROCEDURE
Intervention: Venipuncture for blood sample collection
Description: Analysis samples from the blood sample collection at specific time points.

Intervention type: PROCEDURE
Intervention: Venipuncture for blood sample collection
Description: Analysis samples from the blood sample collection at specific time points.

Intervention type: PROCEDURE
Intervention: Venipuncture for blood sample collection
Description: Analysis samples from the blood sample collection at specific time points.

Intervention type: PROCEDURE
Intervention: Venipuncture for blood sample collection
Description: Analysis samples from the blood sample collection at specific time points.
Study: NCT00277537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: 320mg BD 12 weeks followed by 40 weeks open label

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: BD for 12 weeks
Study: NCT03771625

Intervention type: RADIATION
Intervention: radiotherapy
Description: whole brain with/without spinal cord
Study: NCT02141061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate, Proellex 12 mg Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate, Proellex 12 mg Formulation A
Study: NCT01194648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transperineal prostate biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transrectal prostate biopsy